keyword
MENU ▼
Read by QxMD icon Read
search

dutasteride

keyword
https://www.readbyqxmd.com/read/28102554/what-are-the-predicting-factors-for-the-therapeutic-effects-of-dutasteride-in-male-patients-with-lower-urinary-tract-symptoms-investigation-using-a-urodynamic-study
#1
Yoshihisa Matsukawa, Masashi Kato, Yasuhito Funahashi, Tsuyoshi Majima, Tokunori Yamamoto, Momokazu Gotoh
AIMS: We investigated predicting factors for the therapeutic effects of dutasteride in patients with lower urinary tract symptoms (LUTS) due to benign prostatic enlargement (BPE) based on a urodynamic study (UDS). METHODS: This was a single-center, prospective study involving 120 male outpatients with LUTS. They received 0.5 mg of dutasteride per day for 12 months. IPSS, OABSS, IPSS-QOL, and UDS were used for assessing subjective and objective symptoms prior to and 12 months after administration...
January 19, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28075168/transurethral-resection-of-prostate-and-bleeding-a-prospective-randomized-double-blind-placebo-controlled-trial-to-see-efficacy-of-short-term-use-of-finasteride-and-dutasteride-on-operative-blood-loss-and-prostatic-micro-vessel-density
#2
Ankur Bansal, Aditi Arora
OBJECTIVE: To evaluate the effects of short term use of finasteride and dutasteride on the amount of intraoperative blood loss and microvessel density (MVD) of prostatic stromal and suburethral tissues in the patients with benign prostatic hyperplasia (BPH) prior to transurethral resection of prostate (TURP). METHODS: The study involved 450 male patients who planned to have TURP and were prospectively randomized into 3 groups (150 patients each). Group 1 received placebo, group 2 received finasteride 5 mg/day and group 3 received dutasteride 0...
January 11, 2017: Journal of Endourology
https://www.readbyqxmd.com/read/28061966/new-treatments-for-hair-loss
#3
S Vañó-Galván, F Camacho
The treatment of hair loss is an important part of clinical dermatology given the prevalence of the problem and great impact on patients' quality of life. Many new treatments have been introduced in recent years. This review summarizes the main ones in 4 groups: a) For androgenetic alopecia, we discuss new excipients for oral minoxidil, dutasteride, and finasteride as well as new forms of topical application; prostaglandin agonists and antagonists; low-level laser therapy; and regenerative medicine with Wnt signaling activators and stem cell therapy...
January 3, 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/28024967/extent-of-baseline-prostate-atrophy-is-associated-with-lower-incidence-of-low-and-high-grade-prostate-cancer-on-repeat-biopsy
#4
Dmo Freitas, G L Andriole, R Castro-Santamaria, S J Freedland, D M Moreira
OBJECTIVES: To evaluate whether baseline prostate atrophy (PA) extent is associated with prostate cancer (PCa) incidence at 2-year repeat prostate biopsy in a clinical trial with systematic biopsies. METHODS: We performed a retrospective analysis of 3,165 men 50-75 years-old with prostate-specific antigen (PSA) between 2.5-10ng/mL and a prior negative biopsy in the placebo arm of the Reduction by Dutasteride of PCa Events (REDUCE) trial who underwent a 2-year repeat biopsy...
December 23, 2016: Urology
https://www.readbyqxmd.com/read/28006778/a-systematic-review-and-meta-analysis-of-the-effects-on-dutasteride-treatment-for-reducing-surgical-blood-loss-during-transurethral-resection-of-the-prostate
#5
Jian Ren, Shicong Lai, Zhaoqiang Jiang, Xin Xu, Tongxiang Diao, Nikesh Thiruchelvam, Guan Zhang
OBJECTIVE: This systematic review and meta-analysis were performed to evaluate the efficacy of preoperative dutasteride treatment for reducing surgical blood loss in patients undergoing transurethral resection of the prostate (TURP). METHODS: A systematic search was performed from the electronic databases including PubMed, EMBASE, and Cochrane Library by May 2016. We followed the search strategy based on Preferred Reporting Items for Systematic Reviews and Meta-analysis statement when examining the literature...
December 23, 2016: Urologia Internationalis
https://www.readbyqxmd.com/read/28004415/serum-cholesterol-and-risk-of-lower-urinary-tract-symptoms-progression-results-from-the-reduction-by-dutasteride-of-prostate-cancer-events-study
#6
Tom Feng, Lauren E Howard, Adriana C Vidal, Daniel M Moreira, Ramiro Castro-Santamaria, Gerald L Andriole, Stephen J Freedland
OBJECTIVE: To determine if cholesterol is a risk factor for the development of lower urinary tract symptoms in asymptomatic men. METHODS: A post-hoc analysis of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study was carried out in 2323 men with baseline International Prostate Symptom Score <8 and not taking benign prostatic hyperplasia or cholesterol medications. Cox proportion models were used to test the association between cholesterol, high-density lipoprotein, low-density lipoprotein and the cholesterol : high-density lipoprotein ratio with incident lower urinary tract symptoms, defined as first report of medical treatment, surgery or two reports of an International Prostate Symptom Score >14...
December 22, 2016: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/27990661/association-of-obesity-related-hemodilution-of-prostate-specific-antigen-dihydrotestosterone-and-testosterone
#7
Zachary Klaassen, Lauren E Howard, Daniel M Moreira, Gerald L Andriole, Martha K Terris, Stephen J Freedland
BACKGROUND: Prostate-specific antigen (PSA) hemodilution is the leading theory for lower PSA values in obese men. However, testosterone and dihydrotestosterone (DHT), which are necessary for PSA production, are reduced in obese men. We assessed the relationship of body mass index (BMI) and PSA, taking into consideration the effect of testosterone and DHT. METHODS: Among 8,122 participants in Reduction by Dutasteride of Prostate Cancer Events (REDUCE), complete data were available for 7,275...
December 19, 2016: Prostate
https://www.readbyqxmd.com/read/27981373/-combined-treatment-of-bps-with-tamsulosin-and-finasteride-literature-review-and-prescription-data
#8
K Höfner, S Ulrich, R Berges
Combined therapy of benign prostatic syndrome (BPS) with α1-blockers and 5α-reductase (5AR)-inhibitors is recommended according to two leading studies on doxazosin/finasteride and tamsulosin/dutasteride for all 10 in Germany possible combinations (five α1-blockers and two 5AR inhibitors). Because tamsulosin and finasteride predominate in the treatment of BPS in Germany, the role of the combination tamsulosin/finasteride and its scientific basis from clinical studies has been investigated. A pharmacoepidemiological extrapolation from receipts of pharmacy data centres showed a strong increase of the combination tamsulosin/finasteride since 2003...
December 15, 2016: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/27971355/cost-effectiveness-of-combination-therapy-with-dutasteride-tamsulosin-an-analysis-based-on-conduct-trial
#9
L A Vallejo-Aparicio, B Miñana López, F J Brenes, J M Molero, A Fernández-Pro, A Huerta, J M Cozar
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27871928/the-effect-of-dutasteride-on-magnetic-resonance-imaging-defined-prostate-cancer-mapped-a-randomized-placebo-controlled-double-blind-clinical-trial
#10
Caroline M Moore, Nicola L Robertson, Fatima Jichi, Adebiyi Damola, Gareth Ambler, Francesco Giganti, Ashley J Ridout, Simon R J Bott, Mathias Winkler, Hashim U Ahmed, Manit Arya, Anita V Mitra, Neil McCartan, Alex Freeman, Charles Jameson, Ramiro Castro, Giulio Gambarota, Brandon J Whitcher, Clare Allen, Alex Kirkham, Mark Emberton
PURPOSE: Dutasteride, which is licensed for symptomatic benign prostatic hyperplasia, has been associated with a lower progression rate of low risk prostate cancer. We evaluated the effect of dutasteride on prostate cancer volume as assessed by T2-weighted magnetic resonance imaging. MATERIALS AND METHODS: In this randomized, double-blind, placebo controlled trial, men with biopsy proven, low-intermediate risk prostate cancer (up to Gleason 3 + 4 and PSA up to 15 ng/ml) who had an magnetic resonance imaging visible lesion of 0...
November 19, 2016: Journal of Urology
https://www.readbyqxmd.com/read/27866006/the-cardiovascular-safety-of-dutasteride
#11
Sean C Skeldon, Erin M Macdonald, Michael R Law, Anjie Huang, J Michael Paterson, Muhammad M Mamdani, David Juurlink
PURPOSE: Randomized controlled trials suggest an increased risk of heart failure with dutasteride, which inhibits both the type 1 and type 2 isoforms of 5-α reductase. In contrast, no such association has been suggested for finasteride, which selectively inhibits the type 2 isoform. We investigated the risk of cardiovascular events among patients receiving dutasteride relative to finasteride. MATERIALS AND METHODS: Population-based cohort study of Ontario men aged 66 years or older who commenced treatment with dutasteride or finasteride between October 1, 2005 and March 31, 2015...
November 16, 2016: Journal of Urology
https://www.readbyqxmd.com/read/27864106/withdrawn-transurethral-resection-of-prostate-and-bleeding-a-prospective-randomized-double-blind-placebo-controlled-trial-to-see-efficacy-of-short-term-use-of-finasteride-and-dutasteride-on-operative-blood-loss-and-prostatic-microvessel-density
#12
Aditi Arora, Ankur Bansal, Bimalesh Purkait, Ashok Kumar Sokhal, Ved Bhaskar, Priyank Yadav, Satyanarayan Sankhwar
This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
November 15, 2016: Urology
https://www.readbyqxmd.com/read/27813338/dutasteride-mediated-morphological-changes-in-the-genitourinary-tract-associated-with-altered-expression-patterns-of-the-androgen-and-estrogen-receptors-in-male-rats
#13
N Enatsu, K Chiba, K Sumii, T Fukuda, K Okada, K Matsushita, M Fujisawa
We evaluated the effects of dutasteride on the genitourinary tract using fifteen 8-week-old male Sprague-Dawley rats. Animals were divided into three groups comprising five animals each and treated as follows. Group A was a control group, members of Group B received oral administration of dutasteride 0.1 mg/kg/day from the age of 8 to 16 weeks, and members of Group C were castrated at the age of 8 weeks. All rats were killed at the age of 16 weeks for the sample collection of blood, bladder, prostate, seminal vesicles, and penis...
November 3, 2016: Andrology
https://www.readbyqxmd.com/read/27789379/a-new-label-free-screen-for-steroid-5%C3%AE-reductase-inhibitors-using-lc-ms
#14
Jukkarin Srivilai, Karma Rabgay, Nantaka Khorana, Neti Waranuch, Nitra Nuengchamnong, Kornkanok Ingkaninan
Steroid 5α-reductase (S5αR) plays an important role in metabolizing testosterone into active androgen dihydrotestosterone (DHT) which is involved in many androgen dependent disorders, such as androgenic alopecia, benign prostatic hyperplasia and acne. The method for screening for S5αR inhibition is key in finding new antagonists. In this study, the label-free S5αR inhibitory assay using LC-MS was developed. S5αR type 1 enzyme was obtained from LNCaP prostate cancer cells. The enzymatic assay was optimised for enzyme-substrate (testosterone) concentration, NADPH-cofactor concentration, solvent tolerance, enzyme activity stability and incubation time...
December 2016: Steroids
https://www.readbyqxmd.com/read/27727093/-lower-urinary-tract-symptoms-and-pelvic-floor-dysfunction-in-renal-transplant-candidates-and-recipients
#15
R Thuret, S Hurel, F Kleinclauss, M O Timsit
OBJECTIVES: To describe lower urinary tract symptoms (LUTS) and their management in renal transplant candidates and recipients. MATERIAL AND METHODS: Relevant publications were identified through Medline (http://www.ncbi.nlm.nih.gov) and Embase (http://www.embase.com) database using the following keywords, alone or in association: "transplantation", "prostate hyperplasia", "transurethral resection of prostate", "urinary incontinence", "LUTS", "pelvic floor dysfunction"...
November 2016: Progrès en Urologie
https://www.readbyqxmd.com/read/27683182/a-phase-ii-trial-of-abiraterone-combined-with-dutasteride-for-men-with-metastatic-castration-resistant-prostate-cancer
#16
Rana R McKay, Lillian Werner, Elahe A Mostaghel, Rosina Lis, Olga Voznesensky, Zhenwei Zhang, Brett T Marck, Alvin M Matsumoto, Liran Domachevsky, Katherine A Zukotynski, Manoj Bhasin, Glenn J Bubley, Bruce Montgomery, Philip W Kantoff, Steven P Balk, Mary-Ellen Taplin
PURPOSE: Despite the efficacy of abiraterone, a CYP17A1 inhibitor, in metastatic castration-resistant prostate cancer (CRPC), nearly all patients develop resistance. The purpose of this phase II study was to evaluate mechanisms of resistance to more complete androgen synthesis inhibition with abiraterone and dutasteride. EXPERIMENTAL DESIGN: Eligible patients with metastatic CRPC underwent a baseline metastasis biopsy. Patients received abiraterone and prednisone for two 4-week cycles...
September 28, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27672412/adverse-effects-and-safety-of-5-alpha-reductase-inhibitors-finasteride-dutasteride-a-systematic-review
#17
REVIEW
Jason M Hirshburg, Petra A Kelsey, Chelsea A Therrien, A Carlo Gavino, Jason S Reichenberg
Finasteride and dutasteride, both 5-alpha reductase inhibitors, are considered first-line treatment for androgenetic hair loss in men and used increasingly in women. In each case, patients are expected to take the medications indefinitely despite the lack of research regarding long-term adverse effects. Concerns regarding the adverse effects of these medications has led the United States National Institutes of Health to add a link for post-finasteride syndrome to its Genetic and Rare Disease Information Center...
July 2016: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/27668569/comparing-clinical-and-economic-outcomes-associated-with-early-initiation-of-combination-therapy-of-an-alpha-blocker-and-dutasteride-or-finasteride-in-men-with-benign-prostatic-hyperplasia-in-the-united-states
#18
Maral DerSarkissian, Yongling Xiao, Mei Sheng Duh, Patrick Lefebvre, Andrine R Swensen, Christopher F Bell
BACKGROUND: Benign prostatic hyperplasia (BPH) is a common disease in men that is characterized by lower urinary tract symptoms. Pharmacologic treatment with alpha blockers (ABs) and 5-alpha reductase inhibitors (5ARIs) is recommended to alleviate symptoms, prevent disease progression that can lead to complications, and reduce health care costs. OBJECTIVE: To compare clinical, economic, and health care resource utilization outcomes among BPH patients treated with early continuous combination AB and 5ARI therapy (dutasteride vs...
October 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27659058/risk-of-erectile-dysfunction-associated-with-use-of-5-%C3%AE-reductase-inhibitors-for-benign-prostatic-hyperplasia-or-alopecia-population-based-studies-using-the-clinical-practice-research-datalink
#19
Katrina Wilcox Hagberg, Hozefa A Divan, Rebecca Persson, J Curtis Nickel, Susan S Jick
OBJECTIVE:  To estimate the risk of erectile dysfunction in men who used 5-α reductase inhibitors to treat benign prostatic hyperplasia or alopecia. DESIGN:  Cohort studies with nested case-control analyses. SETTING:  UK Clinical Practice Research Datalink. POPULATION:  Two populations of men free of risk factors for erectile dysfunction and other sexual dysfunction or its treatment: men aged 40 or more with benign prostatic hyperplasia who received a prescription for a 5-α reductase inhibitor (finasteride or dutasteride) or α blocker, or both, and men aged 18-59 with alopecia...
September 22, 2016: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/27644229/dutasteride-for-the-prevention-of-prostate-cancer-in-men-with-high-grade-prostatic-intraepithelial-neoplasia-results-of-a-phase-iii-randomized-open-label-3-year-trial
#20
Daimantas Milonas, Stasys Auskalnis, Giedrius Skulcius, Inga Gudinaviciene, Mindaugas Jievaltas, Steven Joniau
PURPOSE: High-grade prostatic intraepithelial neoplasia (HGPIN) is a potential precursor of prostate cancer (PCa), and patients with HGPIN are at high risk for PCa development. Objective of our study was to evaluate the efficacy of dutasteride 0.5 mg in PCa prevention among men with isolated HGPIN on biopsy. METHODS: This prospective, randomized, phase III, open-label 3-year trial assessed dutasteride versus active surveillance in patients with HGPIN. Patients were randomized to dutasteride 0...
September 19, 2016: World Journal of Urology
keyword
keyword
43774
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"